Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Evaxion Biotech AS (EVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: EVAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.25
1 Year Target Price $13.25
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -48.38% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.07M USD | Price to earnings Ratio - | 1Y Target Price 13.25 |
Price to earnings Ratio - | 1Y Target Price 13.25 | ||
Volume (30-day avg) 2 | Beta 0.14 | 52 Weeks Range 1.20 - 17.75 | Updated Date 08/15/2025 |
52 Weeks Range 1.20 - 17.75 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -431.34% |
Management Effectiveness
Return on Assets (TTM) -37.07% | Return on Equity (TTM) -206.44% |
Valuation
Trailing PE - | Forward PE 3.57 | Enterprise Value 23114396 | Price to Sales(TTM) 5.49 |
Enterprise Value 23114396 | Price to Sales(TTM) 5.49 | ||
Enterprise Value to Revenue 7.02 | Enterprise Value to EBITDA -0.59 | Shares Outstanding 6316570 | Shares Floating 155104950 |
Shares Outstanding 6316570 | Shares Floating 155104950 | ||
Percent Insiders 23.07 | Percent Institutions 6.89 |
Upturn AI SWOT
Evaxion Biotech AS
Company Overview
History and Background
Evaxion Biotech AS, founded in 2008, is a clinical-stage biotechnology company specializing in developing immunotherapies to treat cancer and infectious diseases. It focuses on harnessing the power of the human immune system through innovative technologies.
Core Business Areas
- Cancer Immunotherapies: Developing personalized cancer immunotherapies based on patient-specific tumor mutations to stimulate the immune system to target and destroy cancer cells.
- Infectious Disease Vaccines: Creating prophylactic vaccines against infectious diseases by identifying and targeting highly conserved antigens, aiming to induce broad and durable immunity.
Leadership and Structure
The leadership team includes experienced professionals in biotechnology, immunology, and clinical development. The organizational structure is based on research & development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- EVX-01 (Cancer Immunotherapy): A personalized cancer immunotherapy designed to treat melanoma. It is in clinical development (Phase 2b). Competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo) and other companies developing personalized immunotherapies. Market share data not publicly available due to clinical stage.
- EVX-B1 (Infectious Disease Vaccine): A novel vaccine candidate targeting bacterial infections. It is in pre-clinical stages. Competitors include large pharmaceutical companies that develop broad spectrum antibiotics. Market share data not publicly available due to pre-clinical stage.
- EVX-A20 (Cancer Immunotherapy): A novel immunotherapy designed to treat adenocarcinoma. It is in clinical development (Phase 1/2a). Competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo) and other companies developing personalized immunotherapies. Market share data not publicly available due to clinical stage.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense research and development, high regulatory hurdles, and significant potential for innovation and growth, especially in cancer and infectious disease treatments.
Positioning
Evaxion is a clinical-stage biotech company focused on personalized immunotherapies and vaccine development. Its competitive advantage lies in its AI-immunology platform, PIONEER, which is used to identify relevant tumor mutations for personalized cancer immunotherapies.
Total Addressable Market (TAM)
The total addressable market (TAM) for cancer immunotherapies and infectious disease vaccines is substantial, estimated in the billions of dollars. Evaxion aims to capture a portion of this market through its innovative technologies and clinical development programs. The immunotherapy market size is expected to reach $159.9 Billion by 2032 and the vaccine market is expected to reach $148.6 Billion by 2032
Upturn SWOT Analysis
Strengths
- Proprietary AI-immunology platform (PIONEER)
- Experienced leadership team
- Personalized approach to cancer immunotherapy
- Novel vaccine development approach
Weaknesses
- Clinical-stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources
- High cash burn rate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in immunotherapy and vaccine technologies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory challenges
- Market access barriers
- Economic downturn affecting biotech investment
Competitors and Market Share
Key Competitors
- MRK
- BMY
Competitive Landscape
Evaxion faces competition from larger pharmaceutical companies with approved immunotherapies and established market presence. Its advantage lies in its personalized approach and innovative technology, while its disadvantage is its limited resources.
Growth Trajectory and Initiatives
Historical Growth: Evaxion's historical growth has been characterized by advancement of clinical programs and expansion of its proprietary platform.
Future Projections: Future growth is dependent on positive clinical trial outcomes and successful partnerships. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include advancing clinical trials for EVX-01 and EVX-A20, and exploring new applications of its PIONEER platform.
Summary
Evaxion Biotech is a high-risk, high-reward clinical-stage company with a proprietary AI-immunology platform. Its strengths include a personalized approach to immunotherapy and novel vaccine development. However, its weaknesses include reliance on clinical trial success and limited financial resources. Future success hinges on positive clinical trial results and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evaxion Biotech AS
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Interim CEO & Chief Scientific Officer Dr. Birgitte Rono Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://evaxion.ai |
Full time employees 46 | Website https://evaxion.ai | ||
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.